ArticleMolecular systems biology2005
The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation.
Article in Molecular systems biology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 72 citations in OpenAlex.
- Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC).Pharmaceuticals (Basel, Switzerland) · 2022Review
- Protein disulfide isomerase A1‑associated pathways in the development of stratified breast cancer therapies.International journal of oncology · 2022Article
- YBX1 Enhances Metastasis and Stemness by Transcriptionally Regulating MUC1 in Lung Adenocarcinoma.Frontiers in oncology · 2021Article
- Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.Breast cancer research : BCR · 2020Article
- Schlafen2 mutation in mice causes an osteopetrotic phenotype due to a decrease in the number of osteoclast progenitors.Scientific reports · 2018Article
- The animal nuclear factor Y: an enigmatic and important heterotrimeric transcription factor.American journal of cancer research · 2018Review
- Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.Oncotarget · 2017Review
- Census and evaluation of p53 target genes.Oncogene · 2017Review
- Role of Y Box Protein-1 in cancer: As potential biomarker and novel therapeutic target.Journal of Cancer · 2017Review
- E2 Ubiquitin-conjugating Enzyme, UBE2C Gene, Is Reciprocally Regulated by Wild-type and Gain-of-Function Mutant p53.The Journal of biological chemistry · 2016Article
- The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes.Nucleic acids research · 2016Article
- Expression and significance of telomerase in the nucleus pulposus tissues of degenerative lumbar discs.Biomedical reports · 2015Article
- Therapeutic targets of triple-negative breast cancer: a review.British journal of pharmacology · 2015Review
- p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways.Oncotarget · 2015Article
- E2F1-Mediated Induction of NFYB Attenuates Apoptosis via Joint Regulation of a Pro-Survival Transcriptional Program.PloS one · 2015Article
- iRegulon: from a gene list to a gene regulatory network using large motif and track collections.PLoS computational biology · 2014Article
- Cardiomyocyte cell cycle: Meis-ing something?Cell cycle (Georgetown, Tex.) · 2014Article
- The transcription factor p53: not a repressor, solely an activator.Cell cycle (Georgetown, Tex.) · 2014Article
- A Novel Subset of Human Tumors That Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate Cancers.Cancer informatics · 2014Article
- Human disease locus discovery and mapping to molecular pathways through phylogenetic profiling.Molecular systems biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Deciphering regulatory events that drive malignant transformation represents a major challenge for systems biology. Here, we analyzed genome-wide transcription profiling of an in vitro cancerous transformation process. We focused on a cluster of genes whose expression levels increased as a function of p53 and p16(INK4A) tumor suppressors inactivation. This cluster predominantly consists of cell cycle genes and constitutes a signature of a diversity of cancers. By linking expression profiles of the genes in the cluster with the dynamic behavior of p53 and p16(INK4A), we identified a promoter architecture that integrates signals from the two tumor suppressive channels and that maps their activity onto distinct levels of expression of the cell cycle genes, which, in turn, correspond to different cellular proliferation rates. Taking components of the mitotic spindle as an example, we experimentally verified our predictions that p53-mediated transcriptional repression of several of these novel targets is dependent on the activities of p21, NFY, and E2F. Our study demonstrates how a well-controlled transformation process allows linking between gene expression, promoter architecture, and activity of upstream signaling molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.